Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

At this year’s ASCO Annual Meeting, researchers presented detailed findings concerning biomarkers and rare subtypes of renal ...

Treatment for renal cell carcinoma can vary depending on the size of your tumor, your overall health, how advanced your cancer is, and other factors. Some of the options include surgery ...

Treatment for renal cell carcinoma can vary depending on the size of your tumor, your overall health, how advanced your cancer is, and other factors. Some of the options include surgery, radiation ...

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

Clear cell renal cell carcinoma (ccRCC) is the most prevalent and lethal subtype of renal cell carcinoma (RCC), characterized by a poor prognosis and a high likelihood of distant metastasis.

Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

Purpose. The diagnosis, staging, and management of renal cell carcinoma (RCC) are reviewed. The mechanism, pharmacokinetics, toxicity, clinical activity, and application of molecularly targeted ...

Casdozokitug is under clinical development by Coherus BioSciences and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase ...

Dr. David A Braun delved into detail on the molecular factors driving exceptional responses to immunotherapy in metastatic ...

Alan Tan, MD, discusses factors influencing the choice of immunotherapy plus tyrosine kinase inhibitor vs dual IO in patients ...